Brian Leyland-Jones BSc (1st Class Hons), MB BS, LRCP, MRCS, ECFMG, PhD, FACP, FRCPC Dr. Leyland-Jones is a past Chief of Developmental Therapeutics at the National Cancer Institute (NCI) and has served as principal, co-principal, and co-investigator on more than 100 clinical studies. While at the NCI. he coordinated the…...
Ruggero De Maria, M.D.
President, Alliance Against Cancer; Director, Institute of Pathology, Catholic University, Rome, Italy Professor Ruggero De Maria obtained his M.D. at the University of Catania (1989) and completed his residence training in endocrinology at the University of Palermo (1994). During his postdoc at the Department of Experimental Medicine, University of Rome,…...
Webster Cavenee, Ph.D.
Director of Strategic Alliances, Ludwig Institute for Cancer Research Distinguished Professor of Medicine, University of California San Diego Dr. Cavenee did his graduate and postdoctoral training in cell biology, biochemistry and human genetics. He received his Ph.D. with honors in 1977 from the University of Kansas Medical School and then…...
Alfred Slanetz, Ph.D.
Chairman of the Board Dr. Alfred Slanetz is the founder, president, and chief executive officer of Geneius and has been since its incorporation. He also has served as a director on Geneius’s board since its incorporation in 2012. Geneius, an immuno-oncology start-up, is researching ways to help cancer patients’ immune…...










